VitaVitro Biotech Completes Series B Financing, Focusing on Assisted Reproduction

According to VCBeat, Shenzhen VitaVitro Biotech Co., Ltd. ("VitaVitro Biotech") has completed its Series B financing from Dalton Venture and Weilaizhuoshi Equity Investment Fund. The specific amount of financing was not disclosed. Proceeds from the latest round will be mainly used for R&D and market expansion.

VitaVitro Biotech was established in 2015, headquartered in Shenzhen, China. It is committed to providing advanced technologies for the assisted reproduction industry and integrated solutions for global assisted reproduction laboratories.

VitaVitro's product portfolio, renowned for its unparalleled quality, reliability and safety, covers the entire process of assisted reproduction from oocyte retrieval, cryopreservation, culture to transfer. The company operates in Europe, America, Asia Pacific, and other regions.

In 2017, VitaVitro Biotech began to expand its international market with a new brand, and its main products are outstanding in R&D and technology. This is a key strategy for large-scale international market expansion.

In addition to innovation in R&D and technologies, VitaVitro Biotech attaches great importance to quality control in the production process. Its quality management system meets the requirements of ISO 13485: 2016 standard, with BSI certification while some selected products have obtained EU CE certification and NMPA registration certificate. With the strictest inspection standards set for raw material, production process and finished products, VitaVitro is dedicated to providing the most reliable products.

The whole array of VitaVitro's products has been granted the marketing license of FDA510 (k) in the United States and is being widely used in the assisted reproduction laboratories in America, Asia Pacific and other regions.

The first "brick" in the construction of VitaVitro's integrated solution of assisted reproduction is the company's vitrification freezing and recovery solution. The chief scientist, Professor Vajta, is a world-renowned expert in assisted reproduction, with a proven track record in freezing and cultivating eggs and embryos. At present, the company is actively carrying out clinical trials and establishing scientific research cooperation on vitrified refrigeration carriers and freeze-thaw in China.

Dalton Venture is engaged in early-stage investment and mergers and acquisitions in the healthcare industry, with a focus on medical services and innovative medical technologies. The core team of Dalton Venture is from the medical and healthcare industry, with rich experience in enterprise operation management, investment, and mergers & acquisitions.

Weilaizhuoshi focuses on the early and middle-stage investment in the consumer medical field, such as commercial health insurance, new pharmaceutical retail, and medical devices. The cornerstone investor is BY-HEALTH. Its team consists of senior practitioners in the medical and health industry. Portfolios include Jiayibao, Xiyou Health, VCBeat, etc.